Clinical trial NCT03873285: Method of Genetic Analysis in Genodermatoses
Official title: Development of a Genetic Analysis Method by Mendeliomes and Genomes in the Diagnosis of Genodermatoses and Rare Genetic Diseases With Cutaneous Expression
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Genodermatosis
Rare Genetic Disease With Cutaneous Expression
Keywords: Genodermatosis
genetic
children
Lead sponsor: Queen Fabiola Children's University Hospital
Sponsor class: OTHER
Collaborators: name: Center of Human Genetics - ULB in Brussels
name: Interuniversity Institute of Bioinformatics in Brussels
First posted: 2019-03-13
Enrollment: 100
Sex: ALL
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The goal of the study is to develop a method of genetic diagnosis in two stages, by mendelioma then by genome and transcriptome on fibroblast culture, in genodermatoses and rare diseases with cutaneous expression in the child.

Detailed description: Interventional multicenter prospective study. Patients will be examined by a dermatologist to describe and identify the various skin lesions Collaboration with the geneticist team: clinical examination for relevant cases Patient records will be consulted. Relevant medical information, biological examinations and other complementary examinations will be studied.

A blood sample (10 ml in EDTA tube) will be collected from the patient and his/her parents to store DNA for mediome and genome.

A written parental and child consent (if age-appropriate) will be obtained and a study information sheet will be signed. They will also sign the usual genetic consent request for mendeliome, genome and transcriptome on culture of fibroblasts.

A 4 mm punch skin biopsy (healthy or damaged depending on phenotype and indication) will be performed according to the standard technique.

The fibroblast culture will be performed routinely by the Genetics Center Transcriptome will be done according to the processes set up at the Genetics Center Mendeliome analysis

* Allow the analysis of 4000 rare disease genes
* Will be performed according to routine analyzes of the genetics lab
* Uses the Highlander tools (web)
* Use of de novo filters, autosomal recessive, heterozygous compound, X linked, strong variant (LOF and canonical splice sites)
* Use of rarer filters: exomic or gene deletion, splicing (+/- 12 base pairs around exons)
* In unexplained severe cases, a genome supplemented with the 10Xgenomics method and a transcriptome of fibroblasts will be realized. This double strategy afford to get a genome of high interpretative quality. Genome analysis by the 10Xgenomics method (https://www.10xgenomics.com )
* This method allows us to deconvolate haplotypes and allows the analysis of 16,000 other complementary genes and to obtain precisely defined structural variants.
* The transcriptome will better assess the genomic effects on gene expression.
* The genome and transcriptome will also assess the presence of deep intron mutations and their effect on splicing, and will be a sustainable resource for other long-term projects (analysis of non-coding regions, microRNAs, etc.)

Eligibility criteria: Inclusion Criteria:

* Children between 0 to 18 years old
* Presence of dermatological symptoms suggesting genodermatosis
* Presence of systemic symptoms in an undiagnosed patient associated with dermatological manifestations suggestive of a more rare genetic disorder with cutaneous expression

Exclusion Criteria:

* Mosaicism
* Neurofibromatosis, all type
* Tuberous sclerosis
* Ichthyosis vulgaris
* Suspicion of somatic impairment (giant nevus)

Primary outcomes:
measure: Genetic diagnostic by mendeliome
timeFrame: At time of clinical diagnosis of genodermatosis
Secondary outcomes:
measure: Genetic diagnostic by genome
timeFrame: At time of clinical diagnosis of genodermatosis
measure: Genetic diagnostic by fibroblast transcriptome
timeFrame: At time of clinical diagnosis of genodermatosis
measure: Relevance of dermatological symptoms
timeFrame: At time of clinical diagnosis of genodermatosis
Other outcomes:
Locations:
city: Brussels
country: Belgium
facility: Hôpital Universitaire Des Enfants Rein Fabiola
Study officials:
affiliation: Hôpital Universitaire Des Enfants Rein Fabiola
name: Deborah Salik, MD
role: PRINCIPAL_INVESTIGATOR
References: